|Systematic (IUPAC) name|
|AHFS/Drugs.com||International Drug Names|
|ATC code||L01XD05 (WHO)|
|Molar mass||680.74 g/mol|
Temoporfin (INN) is a photosensitizer (based on chlorin) used in photodynamic therapy for the treatment of squamous cell carcinoma of the head and neck . It is marketed in the European Union under the brand name Foscan. The U.S. Food and Drug Administration (FDA) declined to approve Foscan in 2000. The EU approved its use in June 2001.
Good results were obtained in 21 of 35 patients treated in Germany.
It is photoactivated at 652 nm i.e. by red light.
Patients can remain photosensitive for several weeks after treatment.
- Relationship between subcellular localisation of Foscan and caspase activation in photosensitised MCF-7 cells. Marchal et al. 2007
- Lorenz KJ, Maier H (April 2008). "[Squamous cell carcinoma of the head and neck. Photodynamic therapy with Foscan]". HNO (in German). 56 (4): 402–9. doi:10.1007/s00106-007-1573-1. PMID 17516041.
- O'Connor, Aisling E; Gallagher, William M; Byrne, Annette T (2009). "Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy. Photochemistry and Photobiology, Sep/Oct 2009". Photochemistry and Photobiology.
- http://www.highbeam.com/doc/1P2-18794532.html Foscan approval saves Scotia's skin.
- "Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy". Photochemistry and Photobiology. 2009.
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|